Italy's Medisolve buys Austrian medtech firm MIDES to expand in DACH region
What's the deal? Italian medical-device services provider MedisolveDealroom has a profile for this one. Try Dealroom → has acquired MIDES Healthcare Technology GmbHDealroom has a profile for this one. Try Dealroom →, a Graz-based specialist in the repair, maintenance, and refurbishment of medical technology. Terms were not disclosed. Medisolve, backed by US investment firm H.I.G. CapitalDealroom has a profile for this one. Try Dealroom →, bought the company from Frankfurt-based investor AllistroDealroom has a profile for this one. Try Dealroom →.
What each side brings: MIDES operates across much of Europe, with a strong presence in Germany, Austria, and Switzerland. Medisolve is a European provider of maintenance and integrated services for biomedical equipment, active in Italy, Germany, Austria, Spain, and Portugal.
Why now? The purchase is part of Medisolve's growth strategy, which combines organic expansion with targeted acquisitions. The deal strengthens its footprint in the DACH region and extends its European operations.
What's the endgame? MIDES will bolster Medisolve's laboratory platform and serve as the group's European innovation centre for complex repairs. After the acquisition, Medisolve will post revenue of more than €200 million and employ over 1,000 people across five countries.
Allistro, a mid-market investment firm focused on succession and growth financing in Germany, Austria, and Switzerland, was advised by law firm LutherDealroom has a profile for this one. Try Dealroom → across the deal's jurisdictions. Dr. Dirk Neukirchen, managing director of Allistro, said the firm had "a team at our side that supported the transaction not only with strong legal expertise but also with a keen understanding of our strategic objectives" (translated from German).
The signal: The European market for biomedical-equipment services remains highly fragmented, and Medisolve is positioning itself as a consolidator. Backed by H.I.G. Capital, which manages $74 billion in assets, its cross-border push signals appetite for scale in a sector where specialised regional players are increasingly attractive targets.
Read more: majunke.com
Image credit: NavyMedicine
